August 13, 2025 — ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the quarter ended June 30, 2025, and highlighted progress toward achieving key milestones. The company’s first clinical site for the Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease was activated in June 2025, with patient screening underway and interim results expected in Q4 2025. ZyVersa also reported that an IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity animal model is planned to begin in Q4 2025, and that it has submitted an invited MJFF grant request for funding Parkinson’s disease animal model proof-of-concept studies, with a response expected in Q3 2025. Since the end of Q2 2025, ZyVersa has raised approximately $2.05 million, bringing the year-to-date total to $4.05 million.
Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President, said the company is well positioned to achieve its near-term development milestones. He noted that in June and July 2025, ZyVersa closed two financing transactions providing access to $12 million in capital to advance development of its drug therapies for kidney and inflammatory diseases.
Pipeline Updates:
Cholesterol Efflux Mediator™ VAR 200: The first patient is expected to be treated in a phase 2a clinical trial in patients with DKD in Q3-2025, with interim results in Q4-2025.
Inflammasome ASC Inhibitor IC 100: A diet-induced obesity (DIO) mouse model study is expected to be initiated in partnership with University of Miami Miller School of Medicine Q4-2025.
Second Quarter 2025 Financial Results:
Cash on hand was $0.1 million as of June 30, 2025. On July 8, 2025, the company closed a $2.05M warrant inducement transaction from a current investor.
Research and development expenses were $0.4 million for the three months ended June 30, 2025, a decrease of $0.3 million or 42.2% from the three months ended June 30, 2024.
Net losses were approximately $2.2 million for the three months ended June 30, 2025, with an improvement of $0.6 million or 20% compared to a net loss of approximately $2.8 million, for the three months ended June 30, 2024.
ZyVersa expects its cash and cash equivalents will only be sufficient to fund operating expenses and capital expenditure requirements on a month-to-month basis.
Contact: Karen Cashmere, Chief Commercial Officer, kcashmere@zyversa.com, 786-251-9641
Source: ZyVersa Therapeutics, Inc.
